EP2049110A4 - Diazépans pontés antagonistes du récepteur de l'oréxine - Google Patents

Diazépans pontés antagonistes du récepteur de l'oréxine

Info

Publication number
EP2049110A4
EP2049110A4 EP07796851A EP07796851A EP2049110A4 EP 2049110 A4 EP2049110 A4 EP 2049110A4 EP 07796851 A EP07796851 A EP 07796851A EP 07796851 A EP07796851 A EP 07796851A EP 2049110 A4 EP2049110 A4 EP 2049110A4
Authority
EP
European Patent Office
Prior art keywords
ortexin
diazepans
antagonist
receptor
ortexin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07796851A
Other languages
German (de)
English (en)
Other versions
EP2049110B1 (fr
EP2049110A2 (fr
Inventor
Paul J Coleman
Christopher D Cox
Georgia B Mcgaughey
Anthony J Roecker
John D Schreier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of EP2049110A2 publication Critical patent/EP2049110A2/fr
Publication of EP2049110A4 publication Critical patent/EP2049110A4/fr
Application granted granted Critical
Publication of EP2049110B1 publication Critical patent/EP2049110B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP07796851.9A 2006-07-14 2007-07-13 Diazépans pontés antagonistes du récepteur de l'oréxine Not-in-force EP2049110B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83117806P 2006-07-14 2006-07-14
PCT/US2007/016037 WO2008008517A2 (fr) 2006-07-14 2007-07-13 Diazépans pontés antagonistes du récepteur de l'oréxine

Publications (3)

Publication Number Publication Date
EP2049110A2 EP2049110A2 (fr) 2009-04-22
EP2049110A4 true EP2049110A4 (fr) 2011-08-10
EP2049110B1 EP2049110B1 (fr) 2014-08-20

Family

ID=38923948

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07796851.9A Not-in-force EP2049110B1 (fr) 2006-07-14 2007-07-13 Diazépans pontés antagonistes du récepteur de l'oréxine

Country Status (6)

Country Link
US (1) US8618102B2 (fr)
EP (1) EP2049110B1 (fr)
JP (1) JP2009543785A (fr)
AU (1) AU2007272854B2 (fr)
CA (1) CA2657623A1 (fr)
WO (1) WO2008008517A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CA2688776A1 (en) * 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
JP4881476B2 (ja) 2007-05-23 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション ピリジルピペリジン・オレキシン受容体アンタゴニスト
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
EP2214676B1 (fr) 2007-10-29 2012-11-21 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de l'orexine, de type diazépan substitué
WO2010028033A1 (fr) * 2008-09-05 2010-03-11 Targacept, Inc. Amides de diazabicyclooctanes et leurs utilisations
WO2010028011A1 (fr) * 2008-09-05 2010-03-11 Targacept, Inc. Amides de diazabicyclononanes et leurs utilisations
WO2011050202A1 (fr) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Composés hétérocycliques condensés en tant que modulateurs de récepteur d'orexine
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
WO2011050200A1 (fr) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Composés hétérocycliques condensés en tant que modulateurs de récepteur d'orexine
WO2012058116A1 (fr) * 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibiteurs du canal potassique de la médullaire externe rénale
WO2012085852A1 (fr) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-ylamides
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
WO2013050938A1 (fr) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd Dérivés de 3,7-diazabicyclo[3.3.1]nonane et de 9-oxa-3,7- diazabicyclo[3.3.1]nonane
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
TWI565703B (zh) 2011-11-08 2017-01-11 艾克泰聯製藥有限公司 2-(1,2,3-三唑-2-基)苯甲醯胺及3-(1,2,3-三唑-2-基)吡啶醯胺衍生物
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
US9249160B2 (en) 2012-07-03 2016-02-02 Heptares Therapeutics Limited Orexin receptor antagonists
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CA2902135A1 (fr) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Derives d'amide d'azetidine en tant qu'antagonistes des recepteurs d'orexine
WO2015048091A1 (fr) * 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Régulation de l'ostéogenèse et de la perte de substance osseuse par l'orexine
GB201318222D0 (en) * 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
HRP20181710T1 (hr) 2013-12-04 2018-12-28 Idorsia Pharmaceuticals Ltd Uporaba derivata benzimidazol-prolina
US9732077B2 (en) 2013-12-18 2017-08-15 Merck Sharp & Dohme Corp. Diazepane orexin receptor antagonists
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス, インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
AU2015314851B2 (en) * 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016065587A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Composés pyrazoles antagonistes des récepteurs de l'orexine
WO2016065583A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Antagonistes du récepteur d'orexine à base d'oxazole
WO2016065584A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Antagonistes pipéridine oxadiazole et pipéridine thiadiazole du récepteur de l'orexine
WO2016065586A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole, triazole et tétrazole antagonistes des récepteurs de l'orexine
WO2016065585A1 (fr) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Composés pipéridines isoxazoles et isothiazoles antagonistes des récepteurs de l'orexine
WO2016085784A1 (fr) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Antagonistes de récepteur d'orexine de type méthyl-diazépane
US9994570B2 (en) 2014-11-26 2018-06-12 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
JP2018012645A (ja) * 2014-11-26 2018-01-25 持田製薬株式会社 新規ジアザビシクロ誘導体
WO2016086358A1 (fr) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxyméthyl pipéridines antagonistes du récepteur d'orexine
WO2016086357A1 (fr) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Méthyl oxazoles antagonistes du récepteur d'orexine
JP2018016544A (ja) * 2014-12-03 2018-02-01 持田製薬株式会社 新規ジアザビシクロ[2.2.2]オクタン誘導体
US10011595B2 (en) 2014-12-19 2018-07-03 Merck Sharp & Dohme Corp. Ethyldiamine orexin receptor antagonists
WO2016100162A2 (fr) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Antagonistes oxazoles 5,5-bicycliques du récepteur d'orexine
WO2016095205A1 (fr) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Composés hétéroaryle en tant qu'antagonistes du récepteur de l'hypocrétine
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016095204A1 (fr) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Composés pyrrolidine en tant qu'antagonistes du récepteur de l'hypocrétine
WO2016101119A1 (fr) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Dérivés d'hétéroaryles fusionnés en tant qu'antagonistes des récepteurs des oréxines
WO2016101118A1 (fr) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Antagonistes des récepteurs d'orexine de type amidoéthylazole
WO2017012502A1 (fr) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Composés de quinazoline substitués, ainsi que préparation et utilisations de ceux-ci
WO2017088759A1 (fr) 2015-11-23 2017-06-01 Sunshine Lake Pharma Co., Ltd. Dérivés d'octahydropyrrolo [3, 4-c] pyrrole et leurs utilisations
CN106986859B (zh) * 2016-01-20 2020-02-11 广东东阳光药业有限公司 吲哚衍生物及其用途
MX2018009656A (es) 2016-02-12 2019-02-20 Astrazeneca Ab Piperidinas halo-sustituidas como moduladores de los receptores de orexinas.
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US20190151304A1 (en) 2016-05-10 2019-05-23 Inserm (Institut National De La Santé Et De La Rechercjae Médicale Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
CN107759620B (zh) * 2016-08-16 2021-11-12 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途
GB201702174D0 (en) 2017-02-09 2017-03-29 Benevolentai Bio Ltd Orexin receptor antagonists
GB201707499D0 (en) 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
GB201707504D0 (en) 2017-05-10 2017-06-21 Benevolentai Bio Ltd Orexin receptor antagonists
JOP20190284A1 (ar) 2017-06-14 2019-12-11 Bayer Pharma AG مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
CN107573270B (zh) * 2017-09-29 2019-11-29 河南师范大学 一种α-甲酰基吡咯烷类化合物的合成方法
GB201716871D0 (en) * 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885888A1 (fr) * 1996-02-02 1998-12-23 Nippon Shinyaku Company, Limited Derives de l'isoquinoline et medicaments associes
WO2000044755A1 (fr) * 1999-01-29 2000-08-03 Abbott Laboratories Derives diazabicycliques utiles en tant que ligands du recepteur nicotinique de l'acetylcholine
US6440970B1 (en) * 2000-05-25 2002-08-27 Targacept, Inc. Pharmaceutical compositions and methods for use
US20050101602A1 (en) * 2003-09-19 2005-05-12 Anwer Basha Substituted diazabicycloalkane derivatives

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175395A1 (fr) * 1995-06-02 1996-12-03 Ronald J. Mattson Indanylpiperazines ou homopiperazines, agents melatonergiques
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2196806T3 (es) 1998-05-08 2003-12-16 Smithkline Beecham Plc Derivados de fenilurea y de feniltiourea.
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
DE60015927T2 (de) 1999-02-12 2005-04-07 Smithkline Beecham P.L.C., Brentford Phenylharnstoff und phenylthioharnstoffderivate
WO2000047576A1 (fr) 1999-02-12 2000-08-17 Smithkline Beecham Plc Derives de cinnamide utilises en tant qu'antagonistes des recepteurs de l'orexine-1
AU2804400A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
DE60108236T2 (de) 2000-03-14 2005-12-22 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate
EP1288202A4 (fr) 2000-05-11 2003-07-02 Banyu Pharma Co Ltd Derives n-acyltetrahydroisoquinoline
JP2003534344A (ja) * 2000-05-25 2003-11-18 ターガセプト,インコーポレイテッド ニコチン性コリン受容体リガンドとしてのヘテロアリールジアザビシクロアルカン
US6677354B2 (en) 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
JP4246490B2 (ja) 2000-11-28 2009-04-02 スミスクライン ビーチャム ピー エル シー オレキシン受容体のアンタゴニストとしてのモルホリン誘導体
WO2002051232A2 (fr) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Nouvelles benzazepines et derives heterocycliques associes
IL158463A0 (en) 2001-05-05 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amines
US20040192673A1 (en) 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
BR0210609A (pt) 2001-06-28 2004-07-20 Smithkline Beecham Plc Derivados de amina cìclica n-aroila como antagonistas do receptor da orexina
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
TW200300354A (en) * 2001-11-12 2003-06-01 Jms Co Ltd Injection needle retractable injector
DE10161864A1 (de) 2001-12-14 2003-07-03 Basf Ag Stabilisatorzusammensetzung III
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US6676630B2 (en) 2002-06-04 2004-01-13 Bioject Medical Technologies, Inc. Needle-free injection system
US7260039B2 (en) 2002-06-07 2007-08-21 Lg Electronics, Inc. High-density multi-layer optical disc, method for recording data thereon on layer-by-layer basis, and method for managing spare areas thereof
ES2278197T3 (es) 2002-07-09 2007-08-01 Actelion Pharmaceuticals Ltd. Derivados de 7,8,9,10-tetrahidro-6h-azepino, 6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo(1,2-b)-quinazolinona.
US20060040937A1 (en) 2002-09-18 2006-02-23 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
US7279578B2 (en) 2002-10-11 2007-10-09 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
WO2004052876A1 (fr) 2002-12-12 2004-06-24 Janssen Pharmaceutica, N.V. 4-phenyl-[1,3]-dioxanes substitues
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
MXPA05010137A (es) 2003-03-26 2005-11-16 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
DE602004011204T2 (de) 2003-04-28 2008-12-24 Actelion Pharmaceuticals Ltd. Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
PT1751111E (pt) 2004-03-01 2015-04-01 Actelion Pharmaceuticals Ltd Derivados de 1,2,3,4-tetrahidroisoquinolina substituída
WO2006067224A2 (fr) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Nouveaux composes
WO2006110626A1 (fr) 2005-04-12 2006-10-19 Merck & Co., Inc. Antagonistes du récepteur de l’orexine de type amidopropoxyphényle
WO2006127550A1 (fr) 2005-05-23 2006-11-30 Merck & Co., Inc. Antagonistes des recepteurs d'orexine a base de bis-amide de proline
JP2009503106A (ja) 2005-08-04 2009-01-29 メルク エンド カムパニー インコーポレーテッド アミノエタンスルホンアミドオレキシン受容体アンタゴニスト
JP2009506061A (ja) 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
EP2001485B1 (fr) 2006-03-29 2015-09-09 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de l'orexine sous forme de composés diazépane
PL2049529T3 (pl) 2006-07-14 2011-01-31 Merck Sharp & Dohme Podstawione związki diazepanowe - antagoniści receptora oreksyny
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CA2688776A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885888A1 (fr) * 1996-02-02 1998-12-23 Nippon Shinyaku Company, Limited Derives de l'isoquinoline et medicaments associes
WO2000044755A1 (fr) * 1999-01-29 2000-08-03 Abbott Laboratories Derives diazabicycliques utiles en tant que ligands du recepteur nicotinique de l'acetylcholine
US6440970B1 (en) * 2000-05-25 2002-08-27 Targacept, Inc. Pharmaceutical compositions and methods for use
US20050101602A1 (en) * 2003-09-19 2005-05-12 Anwer Basha Substituted diazabicycloalkane derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008008517A2 *

Also Published As

Publication number Publication date
EP2049110B1 (fr) 2014-08-20
AU2007272854A1 (en) 2008-01-17
US20090239843A1 (en) 2009-09-24
WO2008008517A3 (fr) 2008-12-04
JP2009543785A (ja) 2009-12-10
AU2007272854B2 (en) 2013-08-01
CA2657623A1 (fr) 2008-01-17
EP2049110A2 (fr) 2009-04-22
WO2008008517A2 (fr) 2008-01-17
US8618102B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
EP2049110A4 (fr) Diazépans pontés antagonistes du récepteur de l'oréxine
EP2009992A4 (fr) Antagonistes du récepteur de l'interleukine 8
EP2244575A4 (fr) Antagonistes du récepteur de l'angiotensine ii
BRPI0716364A2 (pt) "conexço tubular"
EP2150115A4 (fr) Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
EP2013701A4 (fr) Désambiguïsation d'entités nommées
EP2047252A4 (fr) Structure de l'ectodomaine du récepteur de l'insuline
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
EP2004654A4 (fr) Antagonistes de la kinase
DK2081951T3 (da) Progesteron-receptorantagonister
EP2013169A4 (fr) Dérivés d'indolamide comme antagonistes du récepteur ep4
HRP20151108T1 (xx) Antagonisti nogo-receptora
BRPI0819014A2 (pt) "descanso de braço"
EP1871752A4 (fr) Antagonistes du récepteur de l' orexine de type amidopropoxyphényle
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
EP2350304A4 (fr) Antagonistes du récepteur 3 de type toll
EP1765805A4 (fr) Antagonistes des recepteurs du cgrp
EP1918681A4 (fr) Détecteur d'angle
EP2365749A4 (fr) Antagonistes de type quinolone du récepteur du neuropeptide s
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
EP2249833A4 (fr) Promédicaments d'antagoniste des récepteurs du cgrp
EP2062892A4 (fr) Agent améliorant l'hypertension

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20090604

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

A4 Supplementary search report drawn up and despatched

Effective date: 20110713

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/04 20060101ALI20110707BHEP

Ipc: C07D 471/08 20060101ALI20110707BHEP

Ipc: A61K 31/44 20060101AFI20110707BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SCHERING CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

17Q First examination report despatched

Effective date: 20120803

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140204

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 683038

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007038240

Country of ref document: DE

Effective date: 20141002

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 683038

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140820

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140820

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141222

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141121

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141220

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007038240

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20150521

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150713

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150713

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20160624

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20160621

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20160801

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140820

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007038240

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170713

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20180330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170713

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170731